




























Since its initial description cell death has appeared as a 
basic biological phenomenon fundamental for 
development and regulation of tissue homeostasis 
whose alteration has important implications in 
pathology [1]. Indeed cell death contributes to tissue 
homeostasis by balancing mitosis and pathology can 
derive from both its increase or decrease. Since the 
initial description of cell death in the 1960s a number of 
different death mechanisms have been described and 
have been classified both on morphological and 
biochemical criteria. A recent paper published in CDD 
[2] by a large number of experts in the field has 
suggested a classification of the different types and is a 
good reference for the subject. This review will mostly 
focus on the role in different human diseases of caspase 
dependent apoptosis Table 1). 
 
Caspase dependent apoptosis (Figure 1) is characterized 
by the activation of pathways leading to the activation 
of a family of proteases: caspases resulting in an 
ordered disruption of the cell without leakage of cellular 
components and induction of inflammation. Apoptosis 
occurs following the activation of specific pathways 
that result in a series of well defined morphological 
events.   The  dying   cell   initially   shows  nuclear  and  
 
 


























cytoplasmic condensation, followed by blebbing of the 
plasma membrane that results in release of small 
membrane-enclosed particles containing cellular 
components known as apoptotic bodies. These are 
rapidly identified by neighbouring cells or professional 
phagocytes and disposed generally without induction of 
inflammation or tissue scarring [3]. Apoptosis depends 
on activation of caspases that will then cleave a number 
of substrates [4] resulting in the biochemical and 
morphological changes typical of this form of death. All 
caspases are synthesized as inactive zymogens that need 
activation to exert their function. Full activation is 
achieved through cleavage of a pro-domain generally by 
other caspases. From a functional point of view we can 
distinguish two types of caspases: up-stream and down-
stream caspases. Up–stream caspases are activated 
when more enzyme molecules are brought in close 
proximity and undergo conformational changes upon 
binding to activation complexes, this results in their 
cleavage and full activation [5, 6]. Once activated they 
will activate additional molecules of the same enzyme 
as well as down stream caspases. Down stream caspases 
on the other hand can only be activated by cleavage of 
the pro-domain by up-stream caspase. Two main 
molecular pathways lead to caspase activation and 
therefore to apoptosis the so-called extrinsic and 
intrinsic pathway. 
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Extrinsic apoptosis indicates a form of death induced by 
extracellular signals that result in the binding of ligands 
to specific trans-membrane receptors, collectively 
known as death receptors (DR) belonging to the 
TNF/NGF family. All death receptors function in a 
similar way: upon ligand binding several receptor 
molecules are brought together and undergo 
conformational changes allowing the assembly of a 
large multi-protein complex known as Death Initiation 
Signalling Complex (DISC) that leads to activation of 
the caspase cascade. In the FAS/CD95 signalling 
complex, that can be used as a prototype of this form of 
death, upon ligand binding FAS recruits, through a 
highly conserved 80 amino acid domain, known as 
death domain (DD), an adaptor molecule: Fas-
associated protein with a DD (FADD). FADD contains 
another conserved protein interaction domain known as 
Death Effector Domain (DED) that binds to an 
homologous domain in caspase 8 leading to its 




































caspase 8 molecules as well as downstream caspases 
such as caspase 3 [7]. 
 
The intrinsic pathway is activated in response to a 
number of stressing conditions including DNA damage, 
oxidative stress and many others. In all cases this 
multiple forms of stress converge on the mitochondria 
and determine mitochondrial outer membrane 
permeabilization (MOMP) this in turn results in 
dissipation of the mitochondrial membrane potential 
and therefore in cessation of ATP production as well as 
release of a number of proteins that contribute to 
caspase activation. At least two molecular mechanisms 
(not mutually exclusive) have been proposed to explain 
how different signals converge at the mitochondria 
resulting in MOMP. One involves the pore forming 
ability of some of the BCL-2 family proteins in the 
outer mitochondrial membrane [8] and the other is the 
result of the opening in the inner membrane of the 
permeability transition pore complex (PTPC), that 
Table 1. Diseases in which alterations of apoptosis are involved
 
Cancer   
Breast  [20, 28, 160, 161] 
Lung  [21, 34, 162] 
Kidney [22] 
Ovary and uterus  [28] 
CNS  [13, 23, 25, 163-165] 
Gastro-enteric trait  [24, 30-32, 166] 
Head and Neck  [167] 
Melanoma  [33, 35, 168-170] 
Lymphomas [18,  19] 
Leukemia [26,  171-178] 
Neurological disorders   
Alzheimer [55,  179-183] 
Parkinson [63,  184,  185] 
Huntington [186-188] 
Amyotrophic Lateral Sclerosis  [189-191] 
Stroke [192-194] 
Cardiovascular disorders   
Ischemia [99,  195-198] 
Heart Failure  [99, 199] 
Infectious diseases   
Bacterial [200-206] 
Viral [150,  207-214] 
Autoimmune diseases   
Systemic Lupus erythematosus  [153, 215, 216] 
Autoimmune lymphoproliferative syndrome  [154, 155] 
Rheumatoid arthritis  [217] 
Thyroiditis [1,  217,  218] 
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(ANT) and the Voltage Dependent Anion Channel 
(VDAC) [9, 10]. The Bcl-2 family proteins are essential 
regulators of this type of apoptosis and are all 
characterized by the presence of at least one Bcl-2 
Homology (BH) domain. From a functional point of 
view they can be classified in anti-apoptotic members 
containing three or four BH domains (such as Bcl-2, 
Bcl-xl, Bcl-w, Mcl-1) and pro-apoptotic members with 
two or three BH domains (such as Bax, Bak, Bcl-xs, 
Bok) or with just one (such as Bad, Bik, Bid, Bim, 
Noxa, Puma). Pro-apoptotic members of the family 
mediate apoptosis by disrupting membrane integrity 
either directly forming pores or by binding to 
mitochondrial channel proteins such as VDAC or ANT, 
while anti-apoptotic members would prevent apoptosis 
by interfering with pro-apoptotic member aggregation. 
The different apoptotic signals are sensed by BH3 only 
proteins that are induced or activated and migrate to the 
mitochondria where they bind the pro-survival members 
of the family removing their block or to the pro-
apoptotic members promoting their aggregation [11]. 
 































released from the mitochondria, these include 
Cytochrome C (CYTC), apoptosis-inducing factor (AIF), 
endonuclease G (endo G), Direct IAP-binding protein 
with low PI (DIABLO, also known as SMAC) and 
others. Once CYTC is released it binds to APAF-1 
inducing the formation of a large complex, known as the 
apoptosome, that recruits caspase 9. In the apoptosome, 
caspase 9 is activated and cleaved and will activate 
additional molecules of caspase 9 as well as down-stream 
caspases such as caspase 3. Due to its lethality the system 
is subject to a number of controls as an example the cyto-
plasm contains a class of proteins known as Inhibitors of 
Apoptosis IAPS that bind and inactivate caspases. Upon 
MOMP the mitochondria also releases proteins such as 
DIABLO/SMAC that bind to IAPS removing their 
inhibition and allowing apoptosis to occur. 
 
The intrinsic and extrinsic pathways are not completely 
independent: in some cells in fact activation of caspase 
8 results in activation of the mitochondrial pathway. In 
this case caspase 8 among other things cleaves a BH3 
only protein BID generating a truncated fragment 
known as truncated BID (tBID) that can permeabilize 
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Based on its role in maintaining tissue homeostasis it is 
not surprising that alterations of apoptosis play an 
important role in cancer development. Moreover defects 
in the apoptotic pathways are responsible for resistance 
to therapy and new therapeutic approaches attempting 
to re-activate these pathways bypassing the block are 
currently being studied [13-17].  Alteration of many 
proteins involved in both intrinsic and extrinsic 
signaling pathways have been described and are in part 
summarized below. It is clear that alterations of up-
stream regulators of these pathways are the most 
common alterations found in cancer cells, as an 
example p53 that can induce cell death in response to a 
number of different stress stimuli, is the most frequently 
mutated gene in human cancers. A description of these 
defects however is beyond the scope of this review. 
 
BCL-2 Family proteins alterations. Bcl-2 was initially 
isolated and characterized in a subset of B-cell 
lymphomas. These tumours carry a typical translocation 
t(14;18) that involves Bcl-2 gene and results in its over-
expression. Thus it appeared that this gene played a role 
in cancer even before his function in regulating 
apoptosis was clearly defined. Since those early days a 
bulk of data have proven the role of Bcl-2 alterations in 
development of cancer including a number of animal 
models. In fact transgenic mice carrying bcl-2 
overexpression are actually susceptible to develop 
different forms of lymphoproliferative disorders [18]. 
Bcl-2 has been found overexpressed not only in B-cell 
lymphomas, but also in a variety of other  cancers such 
as: Hodgkin lymphoma where it seems to be associated 
with worse overall survival  [19]; breast cancer where it 
correlates with tumor aggressiveness, reduced survival 
and resistance to endocrine therapy [20]; non-small and 
small cell lung carcinoma (moreover squamous) [21], 
renal cell carcinoma [22]. A novel polymorphism of the 
BCL-2 promoter (-938C>A) associates with increased 
aggressiveness and worse prognosis in glioblastoma 
multiform [23], chronic lymphocytic leukemia,  as well 
as with a better survival and outcome in breast  and 
ovarian cancers. 
 
In the last years a variety of alterations of the different 
Bcl-2 family members have been described and have 
proven the importance of this group of proteins in 
cancer development. Bax and Bak mutations [24] have 
been described in colon and gastric carcinomas. 
Unexpectedly however neither BAX single KO or 
BAX/BAK double KO show increased tumour 
formation suggesting that compensatory mechanisms 
can allow apoptosis in these cells. Interestingly however 
Bax/pARF double KO mice exhibit an increased variety 
of tumours (sarcomas and carcinomas). Furthermore 
Bax deletion accelerates growth of brain tumours in a 
p53 mutant mice model [25], and of mammary tumours 
in a SV40 large T antigen transgenic mouse model. 
Various BH3 protein alterations have also been 
implicated in cancer development, as an example Bid-
deficient mice are prone to develop a form of chronic 
myelomonocytic leukemia [26], as well as diffuse large 
B-cell lymphoma. 
 
The possibility to target Bcl-2 family members proteins 
to induce apoptosis in cancer cells has been studied for 
many years now and particular attention has been given 
to BH3 only proteins in designing drugs that would 
mimic their pro-apoptotic functions. Some of these are 
currently being tested in phase I/II clinical trials [27-
29]. Antisense oligonucleotides targeting Bcl-2 have 
also been developed and in one case have reached a 
phase III clinical trial in patients with chronic 
lymphocytic leukemia. 
 
Apoptosome defects. Apaf1 inactivation can substitute 
for p53 defects in promoting transformation of myc-
expressing cells, moreover it is frequently silenced or 
inactivated in human cancers. Indeed melanomas, 
leukemias, glioblastomas, and cervical carcinomas have 
been shown to down-regulate Apaf1 by epigenetic 
mechanisms. In addition in some cancers a defective 
Cyt-C dependent caspase 9 activation in the presence of 
normal or elevated Apaf1 levels has been reported but 
the underlying molecular mechanism is still elusive and 
the existence of an unidentified apoptosome inhibitor 
has been suggested. Sequestration of Apaf1 into lipid 
rafts has also been demonstrated in Burkitt lymphoma 
cells providing another molecular mechanism for 
apoptosome dysfunction.  
 
Death receptor pathway defects. Death receptor 
pathways alterations have profound implications in 
cancer and in particular in the mechanism leading to the 
ability of tumours to avoid immune response. In a 
simplistic way one can imagine a scenario in which 
reduced expression of death receptors protects cells 
from the immune system and increased surface (or 
soluble form) expression of death ligands allows killing 
of reactive cells. Indeed CD95 null mice are prone to 
accumulate abnormal T-cells, with splenomegaly and 
lymphoadenopathy and CD95 is lost or mutated in 
several human cancers. In fact CD95 is lost in 
hepatocarcinomas [30], present in less than 5% of 
invasive esophageal cancer cells in 79% of patients [31] 
where it correlates with depth of invasion and nodes 
metastasis, mutated in adult T cell leukemia, down-
regulated in colon cancer [32], ovarian, cervical and 
endometrial cancers, melanoma (where lymphocyte 
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prognosis) [33] and in more than 90% of lung cancers 
[34]. In support of the above mentioned model, down-
regulation of Fas-L leads to decreased tumor volume 
and increased lymphocyte infiltration. Over-expression 
of FAS-L has been reported in hepatocarcinomas, 
esophageal cancers [31], breast cancers, melanomas 
[35], astrocytomas , metastatic colon cancers, gastric 
cancers and  in more than 60% of sarcomas (reaching 
95% in metastatic ones). The soluble form of Fas-L 
(sFas-L), was also found in peripheral blood of cancer 
patients, where it possibly exerts an immunosuppressive 
effect [36, 37].  
 
Defects of the CD95 signaling pathway can also be a 
consequence of alterations of other components of the 
DISC. FADD mutations were reported in non-small-cell 
lung cancer [38] and complete loss was described in a 
subset of diffuse large B-cell lymphoma. However 
FADD defects have also been shown to have a pro-
oncogenic function, probably due to a role of this 
protein different from apoptosis. As an example 
phosphorylated-FADD in lung adenocarcinomas 
correlates with poor survival [39], and its 
overexpression associates with poor prognosis in oral 
squamous cell carcinomas. 
 
A number of evidence highlight the importance of the 
Trail receptor pathway in tumour onset and 
development. The importance of Trail as a tumour 
suppressor is supported by a number of results in 
different animal models including the onset of 
spontaneous haematopoietic malignancies in Trail KO 
mice [40]. As described for CD95 also in the case of 
Trail, defects mostly allow tumour cells to escape 
immune control. Trail receptors 1 and 2 map to 
chromosome 8p21-22 frequently lost in tumours and 
mutations of trail receptors have been described in up to 
20% of various human tumours, including breast 
cancer, head and neck cancers, and non-Hodgkin 
lymphomas. 
 
The possibility to develop cancer therapies based on the 
activation of death receptors has been attractive since 
their discovery, however toxicity of therapies targeting 
TNF and CD95 have greatly reduced the initial 
enthusiasm. The finding that recombinant Trail 
preferentially induced apoptosis in cancer cells while 
sparing normal cells supported by its low or absent 
toxicity in vivo [40, 41] have attracted growing 
interest on the possibility to exploit this pathway for 
cancer therapy. Despite a large investigative effort 
however the reason for this selective activity is poorly 
understood. 
 
Altered caspase activity. Caspases are the final effectors 
of both extrinsic and intrinsic apoptosis, therefore it is 
expected that interfering with their function impairs 
these pathway leading to a survival advantage for 
cancer cells and indeed caspase alterations are not rare 
in a variety of tumours. These can be due to mutations, 
promoter methylation, alternative splicing, and post-
translational modifications. Some of these defects are 
loss of functions, but in other cases mutated caspases 
act as dominant negatives preventing activation also of 
the wild type protein [42]. 
 
Altered caspase function can also be a consequence of 
modified expression of their specific inhibitors, as an 
example cFLIPs that competes with caspase 8 for 
FADD binding, thus preventing its activation, is often 
elevated in tumours, while its down-regulation can 
sensitize tumour cells to therapy. Among caspase 
inhibitors an important role is played by IAPs. Indeed 
alterations of IAPs are found in a variety of human 
cancers and are associated with poor prognosis and 
resistance to therapy. In some cases however loss of 
IAPs correlates with tumour progression complicating 
the issue and suggesting that the role of IAPs has to be 
carefully evaluated based on cell context. While initially 
described as caspase inhibitors now IAPs have been 
recognized to regulate a multitude of other cellular 
functions including regulation of the immune response 
cell migration, mitosis and proliferation [43]. As many 
of these processes are often modified in cancer it is 
clear how alteration of IAPs can play a role in 
tumorigenesis not only as a consequence of altered 
apoptosis. In fact probably the most important pathway 
regulated by IAPs that contributes to cancer 
development is the NF-kB signaling pathway. XIAP, 
cIAP1 and cIAP2 have been shown to regulate this 
pathway and as a consequence inflammation, immunity 
and cell survival. Moreover cIAPs protect from TNF 
killing. In addition, recent findings show a role for IAPs 
in metastatization as a XIAP/survivin complex would 
trigger NF-kB pathway leading to activation of cell 
motility kinases [43]. This however is still a 
controversial issue and other studies show a suppressive 
effect of IAPs on cell mobility.  
 
In any case due to their involvement in cancer 
progression and to their ability to suppress apoptosis 
IAPs have become an attractive therapeutical target, 
leading to the development of IAP inhibitors, some of 
which are based on natural inhibitors such as 
Smac/DIABLO [43, 44]. These drugs appear to be able 
to directly kill cancer cells or at least sensitize them to 
other killing agents while sparing normal cells. A 
number of these compounds are currently entering 
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From a physiological point of view apoptosis plays a 
key role in central nervous development [45, 46], while 
in adult brain it is involved in the pathogenesis of a 
number of diseases including neurodegenerative 




Alzheimer's disease (AD) is the seventh leading cause 
of all deaths in the United States, it is a progressive 
neurodegenerative disorder characterized by 
accumulation of amyloid-β β peptides in extracellular 
senile plaques intra-cellular neurofibrillary tangles 
(NFTs) formation resulting from hyper-phosphorylated 
microtubule-associated protein tau resulting in loss of 
neurons and consequent progressive dementia [47-49].  
Neuronal apoptosis plays an important role in AD 
pathogenesis and caspases seem to be involved also in 
some of the upstream pathological events. Exposure of 
cultured hippocampal neurons to β results in caspase 3 
activation and apoptosis [50]. Aβ is generated following 
sequential cleavage of the amyloid precursor protein 
(APP), and caspase 3 is considered the predominant 
caspase involved in APP cleavage [51, 52]. Tau protein 
is also a substrate for caspase 3; cleavage of tau at its C-
terminus would promote tau hyper-phosphorylation and 
accumulation of NFTs. Moreover, β-induced caspase 3 
activation causes abnormal processing of the tau protein 
in models of AD [53]. APP is also cleaved by caspase 6 
in vivo [54], moreover the N-terminal APP fragment is 
a ligand for death receptor 6 (DR6 also known as 
TNFRSF21) activation of which triggers caspase 6 
dependent axonal degeneration [55].  
 
The potential benefit of inhibiting the intrinsic apoptotic 
pathway has been suggested through the use of a triple 
transgenic AD mouse model wherein overexpression of 
the anti-apoptotic Bcl-2 gene blocked activation of 
caspases 9 and 3; in these conditions, the degree of 
caspase cleavage of tau was limited, the formation of 
plaques and tangles was inhibited, and memory 
retention was improved [56, 57].  
 
Parkinson's disease (PD) is considered the 2nd most 
common chronic neurodegenerative disorder after AD, 
it is associated with movement disorders, tremors, and 
rigidity and is characterized by a specific loss of 
dopaminergic neurons of the substantia nigra. This 
degeneration leads to the formation of fibrillar 
cytoplasmic inclusions known as Lewy bodies. A 
preponderant role of the aberrant activation of intrinsic 
and extrinsic apoptotic pathways in PD pathogenesis 
has been suggested. The involvement of caspases 1 and 
3 in apoptotic cell death has been proved using PD 
animal models [58]. PD has been linked to mutations in 
several genes such as parkin [59], DJ-1, and a gene 
codifying for a mitochondrial kinase, (PTEN)-induced 
kinase 1 (PINK1) [60]. PINK1 function is related to the 
inhibition of mitochondria-dependent apoptosis [61]. In 
human and mouse neurons deleted for PINK1 Bax 
translocation to the mitochondria and cytochrome c 
release to the cytoplasm occur earlier than in control 
cells. Furthermore loss of PINK1 results in elevated 
levels of caspase activation (caspases 3 and 9) [61]. 
Gene-expression profiling studies performed on 
material from patients affected by PD confirmed down-
regulation of PINK1 as well as other anti-apoptotic 
proteins such as Bcl-2 but also found evidence for the 
involvement of the extrinsic pathway. Indeed death 
receptors such as FAS, TNFRSF10B and TNFRSF21 
were up-regulated in PD-affected neurons [62, 63].  
 
Huntington's disease (HD) is a disorder characterized 
by a degenerative process, which affects medium spiny 
striatal and cortical neurons. HD is an autosomal 
dominant disease caused by a mutation in the gene 
encoding the huntingtin protein (htt); this mutation is 
responsible for abnormal expansion of a trinucleotide 
CAG repeat encoding polyglutamine tract expansion in 
the N terminus of htt [64]. The expanded polyglutamine 
alters protein folding, leading to generation of 
aggregates in neurons that seem to be crucial for the 
neurodegenerative process [65, 66]. Mutant htt is 
cleaved by different proteases including caspases [67] 
and accumulation of caspase cleaved fragments is an 
early pathological finding in brains of HD patients [68]. 
Moreover transgenic mice models have demonstrated 
that caspase 6 cleavage of mutant htt is required for the 
development of the characteristic behavioral and neuro-
pathological symptoms. In addition activation of 
caspase 6, is observed before the onset of motor 
abnormalities in HD brains, suggesting that these 
activation could be used as an early marker of the 
disease [69]. 
 
An additional molecular mechanism involves htt-
interacting protein 1 (HIP-1) that binds a polypeptide 
named Hippi (HIP-1 protein interactor) forming a 
complex that can activate caspase 8. The free cellular 
HIP-1 concentration is increased when htt is mutated 
(HD), this would favor the pro-apoptotic Hippi-Hip 
complex formation [70, 71].  
 
Amyotrophic lateral sclerosis (ALS) is a progressive 
neurodegenerative disease characterized by muscle 
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motor neurons [72].  About 10% of cases are familial as 
a result of mutations in the copper-zinc superoxide 
dismutase (SOD1) gene [73], whereas the majority of 
them are sporadic. SOD1 catalyzes conversion of the 
superoxide anion to hydrogen peroxide, however the 
mechanism by which SOD1 mutations cause ALS is 
still not completely understood. Several alterations have 
been identified in ALS and are thought to play a role in 
motor neuron death, including: neurofilament 
abnormalities, aggregate formation, oxidative stress, 
and inflammatory processes [74]. Mice overexpressing 
a human mutant SOD1 develop neuron degeneration, 
and have been used as a model [75, 76]. These mice 
show increased p38 activity that determines increased 
NO production that in turn results in increased FasL 
expression and activation of the extrinsic pathway [77]. 
In addition mutated SOD would localize to the 
mitochondria and directly trigger CYTC release and 
therefore neuronal death [78].  
 
Motor neurons degeneration in ALS is also accompanied 
by inflammation, but the exact mechanism triggering 
inflammatory response remains unclear. Meissner et al 
have recently reported that mutant SOD1 induces IL-1 
beta and promotes caspase 1 activation resulting in 
neuro-inflammation that would contribute to the 
pathogenesis [79]. Finally caspase 1 would act as a 
chronic activator of caspase 3 contributing to neuronal 
loss [80].     
 
Acute CNS insults 
 
Stroke is the leading cause of acquired adult disability 
in USA [81]. Ischemic injury is caused by the loss of 
blood flow to the brain, usually as a consequence of an 
embolism. The decrease in perfusion determines both 
apoptotic and necrotic neuronal cell death in the 
affected region (core) due to energy depletion [82, 83]. 
Around this area of tissues that is irreversibly lost there 
is an area of partially damaged tissue known as 
penumbra that triggers local inflammation. Several 
evidences suggest that inflammation is a crucial event in 
the progression of ischemic brain damage. 
Cyclooxygenase-2 (COX-2) induction and prostaglan-
din E2 elevation have been reported to occur after 
cerebral ischemic insult [84]. Takadera et al showed 
that prostaglandin E2 directly induced apoptosis in 
hippocampal neurons through the activation of caspase 
3 [85], suggesting that a direct effect of prostaglandin 
E2 on hippocampal neurons was mediated by activation 
of the EP2 receptors. The deletion of EP3 receptors is 
known to ameliorate stroke injury in experimental 
stroke models [86], and recently it has been 
demonstrated that EP3 receptors are involved in the 
enhancement of inflammatory and apoptotic response in 
the ischemic cortex [87].  
 
An important role in ischemic brain damage seems to be 
played also by activation of the receptor pathway. TNF 
deletion in mice protects the brain from ischemic 
damage [88]. Fas and FasL levels seem to be increased 
during brain ischemia [89], and interfering with the Fas 
signaling pathway using a blocking anti-FasL antibody 
markedly reduces death of neurons and improves 
functional recovery in animal models of stroke and 
spinal injury. Moreover chronic extrinsic cervical spinal 
cord compression leads to Fas-mediated  apoptosis of 
neurons [90].  
 
C-Jun N-terminal protein kinase (JNK) signaling 
pathway is known to be activated in response to stress 
and ischemia. JNK activation precedes inflammation 
and apoptosis in neuronal cells [91]. Indeed, JNK is 
involved in the regulation of several pro-apoptotic 
proteins such as Bim and inhibition of JNK activity 
attenuated Bax translocation in ischemic neurons [92]. 
 
The involvement of caspases in mediating ischemic 
neuronal cell death has been also demonstrated using 
caspase 1 and 3 KO mice. Cortical neurons from 
caspase 3 -/- mice subjected to oxygen-glucose depriva-
tion, were more resistant to cell death [93], while 
caspase 1 deletion in mice led to reduced production of 
IL-1 beta [94]. Consistently the reduction of IL-1 beta 
function, using specific antagonists, results in 
neuroprotective effects in stroke animal models [95].  
Benchoua et al. proposed activation of different and 
specific pathways in the core or in the penumbra area of 
the brain infarction. In particular, after cerebral 
infarction, in neurons of the core area the first apoptotic 
events are mediated by ligand binding to specific death 
receptors leading to caspase 8 activation. In the 
penumbral area, where mitochondria provide residual 
energy supply, neuronal death is instead induced 
through the mitochondrial pathway [96].    
 
The reperfusion of ischemic tissue usually improves 
clinical outcome of patients, but in others it may 
amplify brain damage due to the ischemia-reperfusion 
injury. Reactive oxygen species (ROS) levels are 
immediately increased after a vessel occlusion is 
cleared, and are considered the main mediators of 
reperfusion injury [97] resulting in the release of 




Adult cardiomyocites are post-mitotic cells, therefore 
this tissue has limited response capability to damage. In 
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types while chronic stress mainly results in hypertrophy 
and myocardial remodelling. Increased evidences 
suggest that slow turnover exists in the normal 
myocardium sustained by stem cells. In pathological 
conditions however death exceeds mitosis resulting in 
heart failure. Apoptosis is very rare in normal 
myocardium with a reported rate of 0.001-0.002% 
however it is increased in both acute and chronic heart 
pathologies were it seems to play an important role [99].  
 
Ischemia reperfusion. Occlusion of coronary arteries 
results in myocardial infarction characterized by 
massive cell death due to deprivation of oxygen, 
nutrients and survival factors. Reperfusion of the 
ischemic tissue is the treatment for acute coronary 
syndromes and limits the size of the lesion but still 
results in damage due to oxidative stress, increased 
cytosolic and mitochondrial calcium levels and 
inflammation determining what is known as reperfusion 
injury.  Apoptosis plays an essential role in the 
pathogenesis of I/R and in general prolonged ischemia 
determines an increase in necrosis while reperfusion 
leads to increased apoptosis. Death during 
ischemia/reperfusion (I/R) is of different kinds: necrotic 
apoptotic and autophagic. Both the intrinsic and 
extrinsic apoptotic pathway are involved in I/R. Indeed 
lpr mice (FAS deficient) show reduced infarct size 
while deletion of both TNFR1 and TNFR2 appears to 
have a protective effect. The role of the intrinsic 
pathway is demonstrated by reduced apoptosis in 
cardiomiocytes over-expressing Bcl-2 or lacking Bax, 
both in vitro and in vivo. As explained above the two 
pathways are connected through Bid cleavage that is 
indeed observed in I/R and Bid KO mice show reduced 
infarct size following I/R. Similarly deletion of PUMA 
(a BH3 only protein activated by p53) also protects 
from apoptosis suggesting the involvement of the p53 
pathway [99].  A number of studies have shown that 
inhibitors of caspases can protect cardiomyocites 
reducing the infarct size. Interestingly over-expression 
of constitutively active Akt or pharmacological 
sustained activation, shows significant protection from 
apoptosis probably by inactivating a number of pro-
apoptotic proteins [100]. 
 
Ischemia damages several mitochondrial components 
including proteins of the oxidative phosphorylation 
complexes and membranes and predisposes them to 
ROS generation [101]. Indeed it is well known that the 
production of ROS is greatly increased during the 
reperfusion phase when oxygen becomes available and 
the mitochondrial respiratory chain is impaired. 
Furthermore this is exacerbated by reduced antioxidant 
defenses.  
Chronic Heart Failure. Heart failure is a complex 
syndrome where the heart is incapable of o meeting the 
metabolic requirement of the body, it can be the result 
of a number of other heart diseases such as myocardial 
infarction, cardio-myopathies and hypertension. In all 
cases it is characterized by left ventricular remodeling 
with chamber enlargement and wall thinning. During 
heart failure cardiomiocytes show a modest increase in 
apoptosis, that however seems to play an important role 
in the pathogenesis [99]. The estimated rate of apoptosis 
in cardiomiocytes in patients with dilated 
cardiomyopathy is between 0.08% and 0.25% and 
increasing apoptosis by only 0.023% in cardiomyocites 
by over-expression of caspase 8 in mice results in 
dilated cardiomyopathy after 2-6 months, that is 
reduced by treatment with caspase inhibitors [102]. 
Multiple stress stimuli have been implicated in 
activating apoptosis in cardiomyocites eventually 
leading to heart failure, these include: excessive 
mechanical stress, ROS, β1 adrenergic receptor 
agonists, angiotensin II, cytokines. The ASK 1-JNK 
pathway seems to play an important role in mediating 
ROS dependent apoptosis in these cells (in part trough 
inactivation of Bcl-2) and regulating left ventricular 
remodeling. Indeed it has been proposed that inhibition 
of Ask-1 can attenuate heart failure [103]. Another 
important pathway seems to involve Gαq, that 
transduces the signal of a number of receptors including 
angiotensin II receptor and α1-adrenergic receptor. 
Over-expression of Gαq in mice heart results in heart 
failure, this is accompanied by over expression of   
Nix/Bnip3L, a BH3 like protein, that can induce 




Pathogenic microorganisms, once inside a host must 
avoid detection and destruction for as long as possible. 
Several pathogens are able to trigger or inhibit apoptosis 
in eukaryotic host cells thus escaping the immune 
system. On the other hand the host can use apoptosis in 
an attempt to defend himself from pathogens. Thus, 
apoptosis has a fundamental role in cellular host-
pathogen interactions that depends on the nature of the 




Although it is outside the scope of this review, it is 
worth mentioning a physiological role for apoptosis in 
bacteria [104]. While initially counterintuitive, several 
studies have underlined how this process may be 
fundamental to bacterial physiology. As an example, 
autolysis, the most common known form of apoptosis in 
bacterial cells, is used by Bacillus subtilis during 
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could interfere with spore germination. Also, when 
exposed to harmful conditions as antimicrobial agents, 
to eliminate defective cells, damaged bacteria self-
digest the cell wall by peptidoglycan hydrolases. 
Moreover, bacterial apoptosis maintains biofilm 
homeostasis by balancing cell death and viability.  The 
increasing knowledge of ancestral forms of apoptosis in 
bacteria will possibly shed light on the evolution and 
molecular mechanisms of apoptosis in eukaryotic cells. 
More relevantly to the subject of this review it is well 
known that bacteria can modulate apoptosis in the host 
favoring their survival and propagation. Several 
apoptogenic molecules have been identified in bacteria 
including common structural components as 
lipopolysaccharide in Gram-negatives [105], lipotechoic 
acid the major constituent of the cell wall of Gram-
positives  and lipoarabinomannan in Mycobacteria 
[106] as well as virulence factors such as exotoxins 
[107], cytolysins [108] and hemolysins [109]. Through 
all these different molecules, bacteria are able to trigger 
both intrinsic and extrinsic apoptotic pathways, here we 
report some examples in different types of both endo-
cellular and extracellular bacteria.  
 
Mycobacterium tuberculosis continues to be a major 
cause of pulmonary infection in the world. It is an 
intracellular parasite capable of establishing a long-term 
infection. It lacks toxins and exerts its virulence through 
its cell wall components [110]. The initial infection 
typically occurs in the alveolar spaces of the lung where 
bacteria are phagocytized by macrophages. In the 
alveolar macrophages, bacteria can survive and replicate 
by preventing fusion of phagosomes with lysosomes 
and thus their cellular lysis [110]. The apoptotic 
response to intracellular pathogens may favour both 
host and parasite in several ways. The host responds to 
the presence of intracellular M. tuberculosis triggering a 
TNF-α-mediated apoptotic pathway. On the contrary, 
bacteria block the TNF-α signalling by up-regulating 
the anti-apoptotic protein Mcl-1 [111]. Recently it has 
been reported that mycobacteria may trigger a non-
classical type of apoptosis to exit host cells [112]. Cell 
death is induced when a threshold of about 20 bacteria 
per macrophage is reached and begins with some typical 
features of apoptosis followed by secondary necrosis 
and release of bacteria. To indicate this non-classical 
mode of apoptosis, Lee and colleagues coined the 
expression “high-MOI apoptosis” [111]. In addition 
Mycobacteria secrete a 19kDa lipoprotein that binds the 
TLR2 receptor that signals through myeloid 
differentiation factor 88 (MyD88) activating apoptosis 
in macrophages  [113].  
 
Pseudomonas aeruginosa is an opportunistic, 
multidrug resistant bacterium that often causes severe 
nosocomial infections such as urinary tract infections, 
pneumonia and bacteremia [114]. P. aeruginosa is also 
responsible for pulmonary infection of patients with 
cystic fibrosis [114]. Although considered as an 
extracellular pathogen, P. aeruginosa can invade and 
survive within different types of cells, in particular 
epithelial respiratory cells. P. aeruginosa triggers cell 
death of lung epithelial cells through the CD95 pathway 
[115]. In vivo experiments have demonstrated that, in 
this case, apoptosis plays a role in the host defence 
against the bacterial infection [115]. Usually, P. 
aeruginosa is aspired into the lower respiratory tract 
after colonizing the oral cavity where oral bacteria may 
facilitate the adhesion and invasion of P. aeruginosa 
into respiratory epithelial cells followed by cytokine 
release and apoptosis [116]. Indeed co-incubation with 
oral bacteria resulted in increased induction of apoptosis 
in host cells [116].   
 
Chlamydiae are obligate intracellular bacteria that have 
adapted to endo-cellular life to the extent of no longer 
being able to replicate outside the host. Chlamydia 
trachomatis is a common sexually transmitted human 
pathogen that causes urogenital infections, 
conjunctivitis and trachoma, while Chlamydophila 
pneumoniae is commonly associated with upper 
respiratory tract infections and can give rise to 
community-acquired pneumonia [117]. Apoptosis-
inhibiting mechanism have been shown in both and 
appear to be similar [105]. During persistent infection, 
Chlamidiae inhibit the release of cytochrome c thus 
blocking apoptosis [118]. The underlying molecular 
mechanism seems to be the proteolytic degradation of 
BH3-only proteins by a chlamydial protease-like 
activity factor (CPAF) [119]. 
 
Enteric pathogens producing Shiga toxins Shiga toxins 
(Stxs) consist of a family of related cytotoxic proteins 
expressed by the enteric pathogen Shigella dysenteriae 
serotype 1 and by several serotypes of 
Enterohaemorrhagic Escherichia coli (EHEC; Shiga 
toxin-producing E. coli, STEC), Shigellae are 
endocellular human-adapted pathogens transmitted by 
the fecal-oral route. STEC are frequently associated 
with severe disease, while not invasive they are able to 
adhere to the intestinal epithelium, causing severe cell 
alterations. Stxs inhibit protein synthesis by inactivation 
of eukaryotic ribosomes [120], they have an AB5 
structure consisting of an enzymatically active A-
subunit and a pentameric B-subunit that bind the toxin 
receptor globotriaosylceramide (Gb3), a neutral 
glycolipid of the globo-series. Stxs are transported  in  a  
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endoplasmic reticulum allowing the transfer of the A-
subunit into the cytosol where it inhibits protein 
synthesis [121]. 
 
Shigellae and EHEC can survive phagocytosis by 
inducing apoptosis through activation of the MAPK 
pathway [107, 122]. Moreover through the prolonged 
activation of the ribotoxic and endoplasmic reticulum 
stress responses, they may initiate apoptosis with the 
rapid activation of caspase 8 and activation of both 
intrinsic and extrinsic pathways [107]. 
 
Interestingly it has also been demonstrated that Stxs 
induce apoptosis in cancer cells and therefore could be 
used as potential anticancer agents [123]. However, an 
obstacle is constituted by the possible toxicity since 
they can also inhibit protein synthesis and trigger 
apoptosis in normal cells. 
 
Helicobacter pylori is the major cause of 
gastroduodenal diseases including peptic ulcer disease, 
gastric lymphoma and gastric adenocarcinoma [124]. 
Vacuolating cytotoxin (VacA) is one of several 
virulence factors identified in H. pylori [124]. In 
addition to cell vacuolation, VacA has other effects on 
different cell types, including membrane channel 
formation, inhibition of T-cell activation and 
proliferation as well as apoptosis. It has been 
documented that VacA induces apoptosis through the 
mitochondrial-dependent pathway in gastric epithelial 
cells [125]. The toxin binds to the RPTPβ (receptor-like 
protein tyrosine phosphatase) receptor and activates the 
pro-apoptotic Bcl-2 family proteins, Bax and Bak. In 
addition, VacA causes down-regulation of JAK-STAT3 
signaling pathway resulting in reduced expression of the 
anti-apoptotic Bcl-2 family proteins, Bcl-2 and Bcl-XL. 
 
Staphylococcus aureus is an ubiquitous bacterium and 
is a part of the human skin and mucosal flora, it can 
engender a variety of diseases and it is one of the most 
common causes of hospital infections. It secretes 
several virulence factors, exotoxins and enzymes, 
involved in the pathogenic mechanisms of the 
bacterium. Two virulence factors have mainly been 
involved in induction of cell death. Superantigen 
enterotoxin B directly binds to both MCH class II 
molecules and to the variable regions of the T-cell 
receptor beta chain (TCRVbeta), cross-linking them in a 
non-specific way, resulting in polyclonal T-cell 
activation which can be followed by cell death [126]. 
Enterotoxin B causes activation-induced cell death of T 
lymphocytes, a process involving TCR binding, 
activation, cell expansion, FAS expression and finally 
PCD. Staphylococcal α-toxin is an hemolysin that 
causes pore formation in the host cell membranes, and 
the consequent disruption of the Na
+/K
+ balance appears 
to trigger apoptosis through regulation of Bcl-2 and 
CYTC release. 
 
Streptococcus pneumoniae is part of the human 
respiratory tract normal flora and is the common cause 
of community-acquired pneumonia, bacterial meningitis 
and bacteremia. Although the virulence of this pathogen 
is in large part determined by its capsular 
polysaccharide, it produces several additional virulence 
factors involved in the infection mechanisms. 
Pneumolysin, like α-toxin as an example, is a pore 
forming exotoxin that can trigger cell death in 
macrophages and other cell types. In human 
macrophages it permeabilizes mitochondrial membranes 
causing cytochrome c release [127]. 
 
Bacillus anthracis is the causative agent of anthrax a 
well known zoonotic disease. Three different primary 
forms of the disease are recognized, the cutaneous, the 
inhalation and the gastrointestinal form. The bacterium 
has two major virulence factors, the poly-D-glutamate 
capsular filaments that plays a major role as an 
invasiveness factor and a toxin complex [128]. The 
toxin complex is a tripartite exotoxin that consists of 
three polypeptide subunits: the protective antigen, the 
edema factor and the lethal factor. The protective 
antigen binds to cellular receptors and mediates the 
entry into the cytosol of the other two factors. The lethal 
factor is a Zn+ metalloprotease that inhibits the MAPK 
pathway causing cell death, while the edema factor is an 
adenylate cyclase that converts ATP to cyclic AMP and 
promotes lethal tissue edema [128]. Both lethal factor 
and edema factor inhibit acquired and innate immune 
responses, allowing the bacteria to multiply in the host.  
 
Listeria monocytogenes is involved in a foodborne 
illness characterized by gastroenteritis, meningitis, 
encephalitis and sepsis [129]. It is a facultative endo-
cellular bacterium that grows in macrophages, epithelial 
cells and fibroblasts [129] and can induce apoptosis in 
several cell types [130]. In hepatocytes, activation of 
apoptosis probably contributes to the resolution of 
infection by: (i) elimination of infected cells and 
reduction of host cells for bacterial replication and (ii) 
allowing access of immune cells to the microorganisms. 
On the contrary, Listeriae can induce cell death to 
reduce the number of phagocytes, lowering antigen 
presentation and breaking efficient adaptative immune 
response. The hemolysin listeriolysin O, the most 
widely studied virulence factor of L. monocytogenes 
promotes apoptosis in host T cells [108], through a 
mechanism that involves loss of mitochondrial 
membrane potential [108]. 
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adults by colonizing the lower intestinal tract [131]. 
Two virulence factors, enterotoxins A and B, largely 
responsible for pathogenicity, are both inducers of 
apoptosis. In intestinal epithelial cells, the toxins 
produce a loss of mitochondrial membrane potential 
followed by release of cytochrome C [130]. The 
decrease of Rho protein activity appears necessary to 
trigger apoptosis [132]. These toxins can also trigger the 




Viruses can only replicate inside host cells that in turn 
possess several defense mechanisms to limit viral 
infection, including cell-mediated immune response, 
inflammation and programmed cell death. Viruses have 
therefore developed several strategies to inhibit or delay 
cell death. On the other hand, some viruses induce 
apoptosis to facilitate the viral spreading and/or to kill 
uninfected cells of the immune system.   
 
A large number of reports and reviews have been 
published on this subject that will provide valuable 
insights [133, 134], here we shortly report some of the 
newest findings on the topic.  
 
Herpesviridae family comprises double-stranded DNA 
viruses that cause common infections in humans. 
Herpesviruses may live latently in specific cell types for 
years and then be activated and cause disease. Varicella-
Zoster virus (VZV) has a short replication cycle and it is 
the etiological agent of chickenpox and after a long 
latency period in ganglia along the entire neuraxis, 
viruses can reactivate and produce shingles and other 
neurological disorders. Despite the bulk of literature on 
the subject the molecular mechanism of  VZV-induced 
cell death is still elusive. A recent study in a melanoma 
cell model suggests a potential role for Bcl-2 [135]. The 
authors show that Bcl-2 mRNA and protein levels 
decrease significantly during progression of the 
infection, resulting in the release of cytochrome C. 
 
Cytomegalovirus has a characteristically long 
replication cycle and causes a sub-clinical infection in 
immune-competent hosts. Cytomegalovirus ensures its 
own survival in the host cells, producing a wide range 
of cell death suppressors [136], among these is a viral 
mitochondrion-localized inhibitor of apoptosis (vMIA) 
with a wide anti-apoptotic activity against both extrinsic 
and intrinsic apoptosis-inducing stimuli. It is 
functionally and structurally similar to Bcl-xL [137] and 
prevents the release of pro-apoptotic factors from 
mitochondria by interaction with the growth arrest and 
DNA damage 45α (GADD45α) protein and Bcl-xL 
[138]. Additionally, vMIA blocks Bax by binding and 
sequestering it at the mitochondrion [139]. 
Cytomegaloviruses also encode an inhibitor of apoptosis 
that suppresses caspase 8 activation. This viral inhibitor 
is highly conserved among mammalian betaher-
pesviruses [136]. Finally Human cytomegalovirus 
infection is known to cause ER stress [140], that would 
normally result in the unfolded protein response (UPR) 
and apoptosis, however cytomegaloviruses encode 
UL38 protein that inhibits ER stress dependent 
apoptosis [140]. 
 
Hepatitis B virus (HBV) is a small hepatotropic virus 
with a partially double-stranded circular DNA 
molecule. HBV can induce several liver diseases 
including asymptomatic infections, acute or fulminant 
hepatitis, chronic hepatitis with progression to cirrhosis 
and hepatocellular carcinoma. Apoptosis can play an 
important role in the progression of HBV infection. To 
date, four HBV proteins can triggers apoptosis in 
various processes: the large surface protein, a truncated 
form of the middle surface protein, the Hbx protein and 
HBSP [141]. 
 
HBV codes for three forms of the surface (envelope) 
protein, known as large, middle and small surface 
proteins [142]. HBV large surface protein induces 
apoptosis in cultured hepatoma cells by activating the 
ER stress pathway [142]. The protein accumulates 
within the ER-Golgi intermediate compartment 
(ERGIC) giving rise to membrane-bound vescicles that 
cause marked vacuolization of the cytoplasm and 
subsequently ER stress [142].  
 
The HBV surface protein MHBs(t) (C-terminally 
truncated middle hepatitis B surface protein) is a potent 
regulator of TRAIL-induced apoptosis through a 
mechanism that requires activation of ERK2 and 
increased cleavage of caspases 3 and 9 [143].  
 
Hepatitis B X protein (HBx) is a small regulatory 
protein involved in the establishment and/or 
maintenance of the chronic state of the infection that 
can induce apoptosis in several ways [144]. It inhibits c-
FLIP, an inhibitor of the intrinsic apoptotic pathway, 
resulting in hyper-activation of caspases 8 and 3 by 
death signals [144]. However a more recent study 
demonstrates that HBx can be either pro- or anti-
apoptotic in rat hepatocytes [145], inhibiting apoptosis 
by activating NF-κB but stimulating it if NF-κB activity 
is inhibited [145]. 
 
HBSP is a splice variant of the HBV DNA polymerase 
with a conserved BH3 domain in the N-terminus. It is 
expressed during viral replication and can induce 
apoptosis functioning as a BH3 only protein [146].  
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strand RNA virus of the Flaviviridae family. HCV 
infection is associated with severe liver disease that 
frequently evolves into chronic disease, cirrhosis, and 
hepatocellular carcinoma. During chronic infection it 
was observed an enhanced hepatocyte apoptosis and up-
regulation of the death inducing ligands CD95/Fas, 
TRAIL and TNFα [147]. However, despite the 
extensive literature the role of apoptosis in chronic 
infection remains a matter of debate, and it also 
questionable if the virus increases or reduces apoptosis 
of infected cells. Moreover the absence of an 
appropriate in vitro infection model has rendered the 
study of this subject quite difficult and the interpretation 
of the data not always univocal.  [147].  
    
Influenza A virus are small viruses of the family 
Orthomyxoviridae with a segmented negative-stranded 
RNA genome, that affects humans and animals. 
Influenza A virus regulates apoptosis in several ways 
through multiple viral proteins with both pro- and anti-
apoptotic activity [148]. The flu virus can induce death 
through activation of TGF-β, converting it from its 
latent form through the viral neuraminidase activity 
[148]. It has also been demonstrated that overexpression 
of the anti-apoptotic protein Bcl-2 results in impaired 
virus production correlating with misglycosylation of 
the viral surface protein haemoagglutinin [148]. The 
block of apoptosis seems to be crucial for viral 
replication, whereas the induction of cell death may be 
implicated in evasion of the immune system. 
 
Human immunodeficiency virus (HIV) type 1 and type 
2 are the causative agents of AIDS. The majority of 
studies have concentrated on the more aggressive HIV-
1. HIV infection is primarily associated with a 
progressive decline in CD4
+ T lymphocytes number, 
consequent immunodeficiency and increased 
susceptibility to opportunistic infections and 
malignancies. The main mechanism for CD4
+ T cell 
depletion is enhanced apoptosis, which can be induced 
by HIV through multiple pathways. HIV triggers 
apoptosis in both infected and uninfected CD4
+ T cells, 
and indeed death of uninfected cells seems to be 
predominant [149, 150]. 
 
HIV enters the cells through the binding of the envelope 
glycoprotein gp120 to the CD4 membrane receptors, 
along with the chemokine co-receptor CXCR4 that 
facilitates membrane fusion between cells to form giant 
multinucleated cells (syncytia) that correlate with 
increased death. Furthermore, death also occurs by 
enhanced membrane permeability due to continuous 
budding of virions and Viral Protein U (Vpu). Once 
inside the host cell, HIV proteases specifically cleave 
and inactivate Bcl-2 and it directly activate procaspase 8 
by proteolysis [151]. Finally, other HIV proteins such as 
negative regulator factor (Nef), envelope glycoprotein 
(Env) and trans-activator of transcription (Tat) are able 
to trigger apoptosis in T-cells by a mechanism that 
involves the Fas-FasL signaling pathway. 
 
As mentioned above HIV also kills uninfected cells 
through several mechanisms, that require the release of 
viral proteins such as gp120, Tat and Nef from infected 
cells into the extracellular environment. These proteins 
in turn trigger apoptosis in bystander cells by different 
mechanisms. Soluble and membrane bound gp120 binds 
different receptors (CD4, CXCR4 and CCR5) inducing 
death both by upregulating Fas and decreasing FLIP and 
activating the intrinsic pathway through down-
regulation of Bcl-2 and up-regulation of Bax. Tat is 
endocytosed by neighbouring cells and up-regulates 
caspase 8 and FasL resulting in death of T helpers and 
neurons, while it appears to kill bystander T cells 
through up-regulation of TRAIL. Induction of apoptosis 
by Nef occurs through unknown mechanisms, however 
genes involved both in the intrinsic and extrinsic 
pathways have been shown to be regulated by this 
protein, in primary human brain microvascular 
endothelial cells suggesting that it can potentially 




A common feature of autoimmune diseases is altered 
tolerance to self antigens and generation of 
autoantibodies. Immune homeostasis and maintenance 
of immune tolerance are strongly dependent on 
apoptosis, moreover defective clearance of dying cells 
results in persistence of autoantigens, therefore 
autoimmune diseases can arise both from defective 
clearance of autoreactive cells or by delayed elimination 
of autoantigens. In addition increased apoptosis as a 
consequence of viral infections, gamma irradiation or 
other stressing conditions may contribute to disease 
onset. More recently it has been suggested that upon 
apoptosis and/or secondary necrosis autoantigens are 
cleaved and modified exposing novel epitopes that are 
recognized by the immune system, again altered or 
delayed clearance as well as prolonged exposure to 
apoptotic inducing stimuli would result in autoimmune 
response. Moreover formation of immune complexes 
would result in secretion of pro-inflammatory cytokines 
such as IL-8, Il-1β, TNFβ and IFN-α resulting in 
chronic inflammation and organ damage. 
 
A large number of evidence support the idea that 
defective apoptosis of immune cells leads to 
autoimmune disease. Lpr and gld mice defective for the 
   
www.impactaging.com                    341                                           AGING,  May 2012, Vol.4 No.5Fas signaling pathway develop lymphoadenopathy and 
splenomegaly and produce a large number of 
autoantibodies developing a disease that resembles 
human systemic lupus erythematosus (SLE), clearly 
demonstrating an essential role for the extrinsic 
apoptotic pathway in controlling autoreactive T and B 
cells and the fact that alteration in apoptosis can 
strongly contribute to autoimmune diseases 
pathogenesis [152, 153]. In humans defects of the Fas 
signaling pathway lead to the autoimmune 
lymphoproliferative syndrome (ALPS) characterized by 
non-malignant lymphoproliferation and autoimmunity 
and have increased incidence of malignancies. 70% of 
these patients carry germ-line heterozygous FAS 
mutations, while the rest have somatic FAS mutations 
or mutations of FAS ligand, caspase 10 and caspase 8. 
In most cases mutations function as dominant negatives 
inhibiting also the function of the wild type protein 
[154]. 
 
While defects in the extrinsic pathway seem to play a 
major role in the immune system it is becoming clear 
that also the intrinsic pathway participates and its 
alterations can contribute to autoimmune disease 
pathogenesis [155]. As an example Bim KO mice have 
been shown to accumulate lymphoid and myeloid cells 
and develop an autoimmune disease, [156, 157]. While 
no mutations of the BH3 only proteins have been 
described in patients with autoimmune diseases, 
reduced levels of Bim were reported in a patient with 
ALPS and over-expression of pro-survival members of 
the bcl2 family have been reported in SLE [155]. 
 
As mentioned above altered clearance of apoptotic cells 
also contributes to autoimmune diseases pathogenesis. 
In fact MGF-8 (a protein essential for macrophage 
clearance of apoptotic cells) defective mice also 
produce a large number of autoantibodies and develop a 
SLE-type autoimmune disease [152]. This is probably 
due to release of cellular material from apoptotic cells 
that have not been cleared by phagocytosis and undergo 
secondary necrosis. These cellular antigens would 
activate autoimmunity. Along the same line mice 
defective for the complement component C1q develop a 
SLE-like glomerulonephritis. Moreover defective 
clearance of apoptotic cells has been demonstrated in 
patients with SLE [158] and macrophages from at least 




Over 50 years of research in the field of cell death have 
clarified many aspects of this fundamental process and 
brought to the attention of scientist its role in a large 
number of different diseases, however exploitation of 
this knowledge in therapy is only at its early steps. We 
expect that in the following years more approaches 
based on control of the different forms of cell death will 
enter the clinical practice. Many problems need to be 
solved, of course, such as activation of alternative death 
pathways when one is pharmaceutically blocked, in 
diseases where survival of the target cell is the final 
goal, as well as unwanted death of “innocent 
bystanders”, when attempting to kill pathological cells 
such as in anti-tumor therapies.    
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